drugset / Trial / NCT00824616

A Study to Test MK-0941 in Adults With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0941-018)

NCT00824616

Phase 2 Completed 68 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to test the effect MK-0941 as add-on therapy for adults taking insulin for Type 2 Diabetes.

Timeline

Start
2009-01
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Subject MK-0941 Small molecule 5 mg
Subject MK-0941 Small molecule 10 mg
Background insulin glargine Protein / enzyme biologic Subcutaneous